Cargando…

Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17

Systemic lupus erythematosus (SLE) is an autoimmune disorder known for its complex pathogenesis, in which cytokines play an essential role. It seems that the modulation of these cytokines may impact disease progression, being considered potential biomarkers. Thus, TNF (tumor necrosis factor)-α and I...

Descripción completa

Detalles Bibliográficos
Autores principales: Richter, Patricia, Macovei, Luana Andreea, Mihai, Ioana Ruxandra, Cardoneanu, Anca, Burlui, Maria Alexandra, Rezus, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572174/
https://www.ncbi.nlm.nih.gov/pubmed/37833861
http://dx.doi.org/10.3390/ijms241914413
_version_ 1785120173051609088
author Richter, Patricia
Macovei, Luana Andreea
Mihai, Ioana Ruxandra
Cardoneanu, Anca
Burlui, Maria Alexandra
Rezus, Elena
author_facet Richter, Patricia
Macovei, Luana Andreea
Mihai, Ioana Ruxandra
Cardoneanu, Anca
Burlui, Maria Alexandra
Rezus, Elena
author_sort Richter, Patricia
collection PubMed
description Systemic lupus erythematosus (SLE) is an autoimmune disorder known for its complex pathogenesis, in which cytokines play an essential role. It seems that the modulation of these cytokines may impact disease progression, being considered potential biomarkers. Thus, TNF (tumor necrosis factor)-α and IL (interleukin)-17 are molecules of great interest in SLE. TNF-α plays a dual role in SLE, with both immunosuppressive and proinflammatory functions. The role of IL-17 is clearly described in the pathogenesis of SLE, having a close association with IL-23 in stimulating the inflammatory response and consecutive tissue destruction. It appears that patients with elevated levels of these cytokines are associated with high disease activity expressed by the SLE disease activity index (SLEDAI) score, although some studies do not confirm this association. However, TNF-α and IL-17 are found in increased titers in lupus patients compared to the general population. Whether inhibition of these cytokines would lead to effective treatment is under discussion. In the case of anti-TNF-α therapies in SLE, the possibility of ATIL (anti-TNF-induced lupus) is a serious concern that limits their use. The use of anti-IL-17 therapies in SLE is a promising option, but not yet approved. Future studies of these cytokines in large cohorts will provide valuable information for the management of SLE.
format Online
Article
Text
id pubmed-10572174
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105721742023-10-14 Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17 Richter, Patricia Macovei, Luana Andreea Mihai, Ioana Ruxandra Cardoneanu, Anca Burlui, Maria Alexandra Rezus, Elena Int J Mol Sci Review Systemic lupus erythematosus (SLE) is an autoimmune disorder known for its complex pathogenesis, in which cytokines play an essential role. It seems that the modulation of these cytokines may impact disease progression, being considered potential biomarkers. Thus, TNF (tumor necrosis factor)-α and IL (interleukin)-17 are molecules of great interest in SLE. TNF-α plays a dual role in SLE, with both immunosuppressive and proinflammatory functions. The role of IL-17 is clearly described in the pathogenesis of SLE, having a close association with IL-23 in stimulating the inflammatory response and consecutive tissue destruction. It appears that patients with elevated levels of these cytokines are associated with high disease activity expressed by the SLE disease activity index (SLEDAI) score, although some studies do not confirm this association. However, TNF-α and IL-17 are found in increased titers in lupus patients compared to the general population. Whether inhibition of these cytokines would lead to effective treatment is under discussion. In the case of anti-TNF-α therapies in SLE, the possibility of ATIL (anti-TNF-induced lupus) is a serious concern that limits their use. The use of anti-IL-17 therapies in SLE is a promising option, but not yet approved. Future studies of these cytokines in large cohorts will provide valuable information for the management of SLE. MDPI 2023-09-22 /pmc/articles/PMC10572174/ /pubmed/37833861 http://dx.doi.org/10.3390/ijms241914413 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Richter, Patricia
Macovei, Luana Andreea
Mihai, Ioana Ruxandra
Cardoneanu, Anca
Burlui, Maria Alexandra
Rezus, Elena
Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
title Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
title_full Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
title_fullStr Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
title_full_unstemmed Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
title_short Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
title_sort cytokines in systemic lupus erythematosus—focus on tnf-α and il-17
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572174/
https://www.ncbi.nlm.nih.gov/pubmed/37833861
http://dx.doi.org/10.3390/ijms241914413
work_keys_str_mv AT richterpatricia cytokinesinsystemiclupuserythematosusfocusontnfaandil17
AT macoveiluanaandreea cytokinesinsystemiclupuserythematosusfocusontnfaandil17
AT mihaiioanaruxandra cytokinesinsystemiclupuserythematosusfocusontnfaandil17
AT cardoneanuanca cytokinesinsystemiclupuserythematosusfocusontnfaandil17
AT burluimariaalexandra cytokinesinsystemiclupuserythematosusfocusontnfaandil17
AT rezuselena cytokinesinsystemiclupuserythematosusfocusontnfaandil17